Biogen
 |
|
| Public | |
| Traded as | |
| Industry | Biotechnology |
| Founded | 1978 (from merger) |
| Founders |
Kenneth Murray Phillip Allen Sharp Walter Gilbert Charles Weissmann |
| Headquarters | Cambridge, Massachusetts, U.S. |
|
Key people
|
Stelios Papadopoulos, Chairman Michel Vounatsos, CEO |
| Products | Alprolix, Avonex, Eloctate, Fampyra, Gazyva*, Plegridy, Rituxan*, Tecfidera, Tysabri |
| Revenue |
 US$ 10.76 billion (2015) <
|
|
US$ 4.89 billion (2015)
|
|
|
US$ 3.55 billion (2015) |
|
| Total assets |
US$ 19.505 billion (2015) |
| Total equity |
 US$ 9.37 billion (2014) |
|
Number of employees
|
7,350 (December 2015) |
| Website | www |
Biogen, Inc. (previously known as Biogen Idec) is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurodegenerative, hematologic, and autoimmune diseases to patients worldwide.
Biogen was founded in 1978 in Geneva by several prominent biologists, including Kenneth Murray of the University of Edinburgh, Phillip Allen Sharp of the Massachusetts Institute of Technology, Walter Gilbert of Harvard (who served as CEO during the start-up phase), Heinz Schaller, University of Heidelberg and Charles Weissmann, University of Zurich (who contributed the first product interferon alpha). Gilbert and Sharp were subsequently honored with Nobel Prizes: Gilbert was recognized in 1980 with the Nobel Prize in Chemistry for his work in understanding DNA sequencing, while Sharp received the Nobel Prize in Physiology or Medicine in 1993 for his discovery of split genes.
...
Wikipedia